Kura Oncology reported a quarterly loss of $0.83 per share, beating the Zacks Consensus Estimate of a $0.88 loss by $0.05 per share. The loss was still wider than the $0.66 per share loss in the same quarter last year, indicating year-over-year deterioration despite the small estimate beat. The update is modestly positive versus expectations but not a strong fundamental inflection.
Kura Oncology reported a quarterly loss of $0.83 per share, beating the Zacks Consensus Estimate of a $0.88 loss by $0.05 per share. The loss was still wider than the $0.66 per share loss in the same quarter last year, indicating year-over-year deterioration despite the small estimate beat. The update is modestly positive versus expectations but not a strong fundamental inflection.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
mildly positive
Sentiment Score
0.15
Ticker Sentiment
